Pacira BioSciences Stock Forecast, Price & News

Pacira BioSciences (NASDAQ:PCRX) Frequently Asked Questions

Is Pacira BioSciences a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences or view top-rated stocks.

How has Pacira BioSciences' stock been impacted by COVID-19 (Coronavirus)?

Pacira BioSciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PCRX stock has increased by 53.9% and is now trading at $54.15.
View which stocks have been most impacted by COVID-19.

When is Pacira BioSciences' next earnings date?

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Pacira BioSciences.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.07. The company had revenue of $127.70 million for the quarter, compared to the consensus estimate of $129.69 million. Pacira BioSciences had a net margin of 12.01% and a trailing twelve-month return on equity of 14.39%. The company's quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the business earned $0.43 EPS.
View Pacira BioSciences' earnings history.

What price target have analysts set for PCRX?

11 brokers have issued 12-month target prices for Pacira BioSciences' shares. Their forecasts range from $57.00 to $93.00. On average, they anticipate Pacira BioSciences' stock price to reach $79.55 in the next year. This suggests a possible upside of 46.9% from the stock's current price.
View analysts' price targets for Pacira BioSciences or view top-rated stocks among Wall Street analysts.

Who are Pacira BioSciences' key executives?

Pacira BioSciences' management team includes the following people:

• David M. Stack, Chairman, Chief Executive & Operating Officer (LinkedIn Profile)
• Charles A. Reinhart, Chief Financial Officer (LinkedIn Profile)
• Roy Winston, Chief Medical Officer (LinkedIn Profile)
• Charles Anthony Laranjeira, Chief Technical Officer
• Jonathan Slonin, Chief Clinical Officer

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pacira BioSciences' key competitors?

Some companies that are related to Pacira BioSciences include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of PCRX's competitors.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (8.27%), Spyglass Capital Management LLC (4.96%), Baillie Gifford & Co. (4.70%), Renaissance Technologies LLC (4.42%), Paulson & CO. Inc. (2.83%) and Stephens Investment Management Group LLC (2.19%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, David M Stack, Dennis Mcloughlin, Donald C Manning, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends for Pacira BioSciences.

Which major investors are selling Pacira BioSciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, Renaissance Technologies LLC, Millennium Management LLC, Schroder Investment Management Group, Dimensional Fund Advisors LP, Assenagon Asset Management S.A., and Peregrine Capital Management LLC. Company insiders that have sold Pacira BioSciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, David M Stack, Donald C Manning, Kristen Marie Williams, Lauren Bullaro Riker, Max Reinhardt, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences or view top insider-selling stocks.

Which major investors are buying Pacira BioSciences stock?

PCRX stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Spyglass Capital Management LLC, Jabodon PT Co., Gagnon Securities LLC, Tributary Capital Management LLC, Schonfeld Strategic Advisors LLC, Tudor Investment Corp Et Al, and Voloridge Investment Management LLC.
View insider buying and selling activity for Pacira BioSciences or or view top insider-buying stocks.

How do I buy shares of Pacira BioSciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $54.15.

How much money does Pacira BioSciences make?

Pacira BioSciences has a market capitalization of $2.41 billion and generates $429.65 million in revenue each year. The company earns $145.52 million in net income (profit) each year or $1.36 on an earnings per share basis.

How many employees does Pacira BioSciences have?

Pacira BioSciences employs 624 workers across the globe.

What is Pacira BioSciences' official website?

The official website for Pacira BioSciences is www.pacira.com.

Where are Pacira BioSciences' headquarters?

Pacira BioSciences is headquartered at 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at (813) 553-6680, via email at [email protected], or via fax at 302-655-5049.